61. 自己免疫性溶血性貧血 Autoimmune hemolytic anemia Clinical trials / Disease details


臨床試験数 : 137 薬物数 : 139 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 152

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05073458
(ClinicalTrials.gov)
March 15, 202228/9/2021Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaWarm Autoimmune Hemolytic Anemia (wAIHA)Drug: parsaclisinib;Drug: placeboIncyte CorporationNULLRecruiting18 Years99 YearsAll100Phase 3United States;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom
2EUCTR2021-002844-66-NL
(EUCTR)
10/03/202229/11/2021Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia Primary Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Parsaclisib (1 mg)
Product Code: INCB050465
INN or Proposed INN: not yet assigned
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: Parsaclisib (2.5 mg)
Product Code: INCB050465
INN or Proposed INN: not yet assigned
Other descriptive name: INCB050465 HYDROCHLORIDE
Incyte CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 3United States;Spain;Ukraine;Austria;Israel;Italy;United Kingdom;France;Canada;Belgium;Poland;Netherlands;Germany;Japan
3EUCTR2021-002844-66-ES
(EUCTR)
03/02/202215/10/2021Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia Primary Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Parsaclisib (1 mg)
Product Code: INCB050465
INN or Proposed INN: Parsaclisib
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: Parsaclisib (2.5 mg)
Product Code: INCB050465
INN or Proposed INN: Parsaclisib
Other descriptive name: INCB050465 HYDROCHLORIDE
Incyte CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 3United States;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;France;Canada;Belgium;Poland;Germany;Netherlands;Japan
4JPRN-jRCT2051210140
30/12/202124/12/2021A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia - PATHWAY Warm Autoimmune Hemolytic Anemia (wAIHA)Group A: Parsaclisib (INCB050465) will be administered QD orally.
Group B: Placebo will be administered QD orally.
Ueda EijiNULLRecruiting>= 18age old<= 99age oldBoth100Phase 3U.S.A;Japan
5EUCTR2021-002844-66-IT
(EUCTR)
23/11/202123/09/2021Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic AnemiaA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia - NA Primary Warm Autoimmune Hemolytic Anemia
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Parsaclisib (1 mg)
Product Code: [INCB050465]
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: Parsaclisib (2.5 mg)
Product Code: [INCB050465]
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Name: trimethoprim-sulfamethoxazole
Product Code: [trimethoprim-sulfamethoxazole]
INN or Proposed INN: TRIMETOPRIM + SULFAMETOSSAZOLO *
Product Name: pentamidine
Product Code: [pentamidine]
INN or Proposed INN: PENTAMIDINA ISETIONATO
Product Name: atovaquone
Product Code: [atovaquone]
INN or Proposed INN: ATOVAQUONE
INCYTE CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 3United States;Spain;Ukraine;Austria;Israel;United Kingdom;Italy;France;Canada;Belgium;Poland;Germany;Netherlands;Japan
6NCT03538041
(ClinicalTrials.gov)
November 21, 201815/5/2018A Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaA Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaAutoimmune Hemolytic AnemiaDrug: ParsaclisibIncyte CorporationNULLActive, not recruiting18 YearsN/AAll25Phase 2United States;Austria;France;Italy
7EUCTR2017-003652-22-IT
(EUCTR)
18/09/201815/01/2021A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia (AIHA)A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia - A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia (AIHA) Autoimmune Hemolytic Anemia (AIHA), immunohemolytic anemia, autoimmune hemolytic anemia, immune complex hemolytic anemia.Warm AIHA, Cold AIHA
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: INCB050465 2.5 mg
Product Code: [INCB050465 2.5 mg]
Product Name: INCB050465 1 mg
Product Code: [INCB050465 1 mg]
INCYTE CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
25Phase 2France;United States;Austria;Italy
8EUCTR2017-003652-22-AT
(EUCTR)
18/07/201829/03/2018A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia (AIHA)A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Autoimmune Hemolytic Anemia (AIHA), immunohemolytic anemia, autoimmune hemolytic anemia, immune complex hemolytic anemia.Warm AIHA, Cold AIHA
MedDRA version: 20.0;Level: LLT;Classification code 10003825;Term: Autoimmune hemolytic anemia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Code: INCB050465 1 mg
INN or Proposed INN: not yet assigned
Other descriptive name: INCB050465 HYDROCHLORIDE
Product Code: INCB050465 2.5 mg
INN or Proposed INN: not yet assigned
Other descriptive name: INCB050465 HYDROCHLORIDE
Incyte CoorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
25Phase 2France;United States;Austria;Italy